Journal article
Potential for novel biomarkers in diabetes-associated chronic kidney disease: Epigenome, metabolome, and gut microbiome
A Lecamwasam, EI Ekinci, R Saffery, KM Dwyer
Biomedicines | MDPI | Published : 2020
Open access
Abstract
Diabetes-associated chronic kidney disease is a pandemic issue. Despite the global increase in the number of individuals with this chronic condition together with increasing morbidity and mortality, there are currently only limited therapeutic options to slow disease progression. One of the reasons for this is that the current-day "gold standard" biomarkers lack adequate sensitivity and specificity to detect early diabetic chronic kidney disease (CKD). This review focuses on the rapidly evolving areas of epigenetics, metabolomics, and the gut microbiome as potential sources of novel biomarkers in diabetes-associated CKD and discusses their relevance to clinical practice. However, it also hig..
View full abstractGrants
Funding Acknowledgements
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Elif I. Ekinci was supported by a Viertel Clinical Investigatorship, Royal Australasian College of Physicians (RACP) Fellowship, EdwardWeary Dunlop Medical Research Foundation, Stroke Foundation and NHMRC research grants. Ekinci's institution has received research funding from Novo Nordisk, Bayer, Sanofi, Dimerix. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.